MO-U.S.-SOYBEAN-EXPORT
6.7.2020 16:19:08 CEST | Business Wire | Press release
A new meta-analytical study reinforces U.S. Soy’s reputation for being a global leader in quality and nutrient-density. The study, entitled, “Chemical composition, protein quality and nutritive value of commercial soybean meals produced from beans from different countries,” demonstrates that not all soybean meals are created equal and that meal from different countries of origin should be treated individually when formulating swine and poultry diets. The data from this study were then processed by the Nutrient Value Calculator (NVC), a software tool constructed by Genesis Feed Technologies, a company built to bring visibility into feed costs. This cost analysis supported the economic benefits of U.S. soybean meal relative to meal from other origins as a key ingredient in poultry rations.
Dr. Gonzalo Mateos, Professor of Animal Science at the University of Madrid in Spain and study co-author, first presented findings from the meta-analysis at the U.S. Soybean Export Council’s (USSEC) Asia Trade Exchange to 850 U.S. Soy customers and soybean industry representatives. This pioneering compilation of research is the most comprehensive quality review of soybean meal that has ever been conducted, and it gives customers greater clarity around soybean meal quality from different countries of origin. The meta-analysis looked at 18 different studies and 1,944 samples to quantify the relationship between country of origin of the bean and the chemical composition and nutritive value of the soybean meal. Soybeans from the following origins were analyzed: Argentina (ARG), Brazil (BRA), USA (USA) and India (IND).
“One of the main points from the study, is that customers should be using different matrices for the evaluation of the nutritional value of soybean meals of different origins,” said Dr. Gonzalo Mateos, Professor of Animal Science at the University of Madrid, Spain . “If they buy only based on protein or vegetable sucrose content, they may buy a product that is actually lower quality. Therefore, it is important to check all of the values that are related to the nutritive value of the soybean meal before making purchase decisions, which this study addresses.”
The data in this meta-analysis forms a new key pillar of the economic evaluation of soybean meal in global markets. Using the Nutrient Value Calculator from Genesis Feed Technologies , the economic value of U.S. soybean meal can be evaluated in global markets using formulas representative of the regional feed manufacturers. Nutrient values and prices of all the other components of the diet are also used in this calculation. The NVC indicates that U.S. soybean meal is the leading contributor to cost reduction in broiler diets.
“Our company was thrilled to participate in this groundbreaking research conducted by the U.S. Soybean Export Council,” said Peter Schott, CEO and Co-Founder of Genesis Feed Technologies . “We hope that buyers take note of the results, purchase more U.S. soy and see a significant reduction in their feed costs. This NVC analyzes economic nutritional value of soybean meals from different origins to give traders and buyers a platform to connect with nutritionists directly to better inform their feed investments.”
When comparing cost reductions with incorporation of data from the aforementioned meta-analytical study, premiums of U.S. soybean meal range from $14.57 to $23.24 per tonne over Argentine soybean meal and range from $2.48 to $10.26 per tonne over Brazilian soybean meal.
“U.S. soy and soybean meal products offer a price advantage and rank first on a number of important nutritional attributes when compared to other origins, including remarkable amino acid and energy profiles,” said Paul Burke, USSEC’s Senior Director for U.S. Soy Marketing . “This will continue to ensure we deliver a valuable, consistent and more economical product that our customers can count on.”
Soybean meal is an important source of protein for the global feed industry, where it is used in livestock, poultry and aquaculture diets. To meet this demand for animal feed, the farmers that grow sustainable U.S. soy not only care about being a reliable supplier but take pride in providing a high-quality product to their international customers.
“The world’s need for a high-quality protein product like U.S. soybean meal will be critical as our population continues to grow. And U.S. farmers around the country are ready and willing to meet that need,” said Monte Peterson, Chairman of USSEC , board member of the American Soybean Association and soybean farmer in Valley City, N.D. “Our soybean farmers provide a consistent, nutritious and efficient source of protein for both the food and feed sectors. This meta-analysis is important because it shows how U.S. soy is the most high-quality and best economic choice, backed by science.”
To learn more and access a summary of the meta-analysis, click here . And register to watch USSEC’s recorded webinar with Dr. Gonzalo Mateos and Genesis Feed Technologies to hear key insights about the meta-analysis and better understand the nutritional value of U.S. soybean meal as compared to different origins.
ABOUT U.S. SOYBEAN EXPORT COUNCIL
The U.S. Soybean Export Council (USSEC) is a dynamic partnership of U.S. soybean producers, processors, commodity shippers, merchandisers, allied agribusinesses and agricultural organizations working to build preference for U.S. soy throughout the world. Through a global network of international offices and strong support in the U.S., USSEC works to build a preference for U.S. soybeans and soybean products, advocates for the use of soy in feed, aquaculture and human consumption, promotes the benefits of soy use through education, and connects industry leaders through a robust membership program. USSEC is partially funded by the United Soybean Board. Learn more at www.ussec.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200706005035/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
